Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for CareDx, Inc. (Nasdaq: CDNA), a precision medicine company focused on genomics‑based transplant diagnostics and related solutions. Through these filings, investors and analysts can review how CareDx reports its financial performance, governance changes, and other material events connected to its transplant‑focused business.
CareDx uses Form 8‑K to disclose current events such as quarterly financial results, preliminary annual results, leadership and board appointments, amendments to its bylaws, and information about shareholder derivative litigation settlements. For example, recent 8‑K filings describe revenue by category (testing services, product, and patient and digital solutions), changes in executive roles, adoption of a majority voting standard for director elections, and court approval milestones for a proposed settlement of shareholder litigation.
In addition to current reports, investors typically consult annual reports on Form 10‑K and quarterly reports on Form 10‑Q for more detailed discussions of CareDx’s transplant diagnostics business, segment information, and risk factors. These periodic reports complement the 8‑K disclosures by providing broader context on the company’s operations in non‑invasive molecular testing, lab products, and patient and digital solutions for transplant care.
On Stock Titan, CareDx filings are updated as they become available from EDGAR and are paired with AI‑powered summaries that highlight key points from lengthy documents. These summaries are designed to help readers quickly understand topics such as revenue composition, governance updates, compensation arrangements, and litigation‑related disclosures, while still allowing direct access to the original SEC filings for detailed review.
CareDx, Inc. director Michael Goldberg exercised stock options to acquire additional common shares. On March 31, 2026, he exercised options covering 26,500 shares of CareDx common stock at exercise prices of $5.02, $4.95, and $1.22 per share.
Following these option exercises, Goldberg directly owned 183,961 shares of CareDx common stock. The exercised options were originally subject to vesting schedules beginning in 2016 and 2017, with monthly vesting thereafter as described in the filing footnotes. No sales or gifts were reported in this filing.
CareDx Inc Schedules an Amendment No. 9 to a Schedule 13G/A showing 0 shares beneficially owned, representing 0% of Common Stock as of 03/13/2026.
The filing explains an internal realignment at The Vanguard Group on 01/12/2026, after which certain Vanguard subsidiaries report holdings separately in reliance on SEC Release No. 34-39538. The filing is signed by a Vanguard officer on 03/26/2026.
CareDx, Inc. reported solid growth for the fourth quarter and full year 2025 and outlined its 2026 outlook, while also announcing a Chief Financial Officer transition. Full‑year 2025 revenue reached $380 million, up 14% from 2024, with Q4 2025 revenue of $108 million, up 25% year over year. Testing services generated $275 million for 2025, rising 10%, and patient and digital solutions and product revenue grew 31% and 19%, respectively. The company posted a 2025 GAAP net loss of $21 million but achieved non‑GAAP net income of $32 million and adjusted EBITDA of $32 million. CareDx ended December 31, 2025 with about $201 million in cash, cash equivalents, and marketable securities after repurchasing $88 million of stock. For 2026, it expects revenue of $420–$444 million and adjusted EBITDA of $30–$45 million. The board appointed Keith Kennedy as Chief Financial Officer and Chief Operating Officer effective February 26, 2026, while Nathan Smith resigned as CFO effective February 25, 2026 and will receive severance, a $91,643 2025 bonus, COBRA reimbursements, and vesting of 5,840 restricted stock units.
CareDx, Inc. files its annual report describing a focused transplant-diagnostics business built around AlloSure, AlloMap, HeartCare, AlloHeme, AlloCell and AlloSeq product lines, plus digital and pharmacy services for transplant centers.
The company reported a net loss of $21.4 million for the year ended December 31, 2025, compared with net income of $52.5 million in 2024, and an accumulated deficit of $735.4 million. In 2025 it performed about 200,000 commercial tests, with Medicare providing roughly 46% of testing-services revenue.
AlloSure blood-based rejection tests (kidney, heart, lung) are reimbursed by Medicare at $2,753 per test effective January 1, 2026, an $88 reduction for AlloSure Kidney. As of February 19, 2026, 51,216,344 common shares were outstanding, and CareDx employed 765 people, mainly in the United States and Europe.
CareDx reported strong growth for 2025 while reshaping its leadership team. Full-year revenue reached $380 million, up 14% from 2024, with Q4 revenue of $108 million, up 25%. Testing services, patient and digital solutions, and product revenue all grew double‑digits.
The company posted a 2025 GAAP net loss of $21 million, but delivered non‑GAAP net income of $32 million and adjusted EBITDA of $32 million. Cash, cash equivalents and marketable securities were about $201 million as of December 31, 2025 after $88 million of share repurchases. For 2026, CareDx guides revenue to $420–$444 million and adjusted EBITDA of $30–$45 million.
The Board appointed Keith Kennedy as Chief Financial Officer and Chief Operating Officer, effective February 26, 2026, following the resignation of CFO Nathan Smith for personal reasons. Smith will receive severance including nine months’ salary, a $91,643 bonus, COBRA premium reimbursement for nine months, and vesting of 5,840 restricted stock units.
CareDx, Inc. (CDNA) received an updated ownership report on its common stock from investment manager Neil Gagnon and related entities. As of the reported date, Gagnon reports beneficial ownership of 3,054,946 shares of CareDx common stock, representing 5.9% of the class.
Within this total, Gagnon Securities LLC reports beneficial ownership of 2,213,827 shares, or 4.3% of the class, and Gagnon Advisors, LLC reports 532,892 shares, or 1.0%. The filing states the securities are not held for the purpose of changing or influencing control of CareDx.
State Street Corporation has filed a Schedule 13G reporting a passive ownership stake in CareDx, Inc. (CDNA). As of 12/31/2025, State Street reports beneficial ownership of 2,737,752 shares of CareDx common stock, representing 5.3% of the outstanding class.
State Street reports shared voting power over 2,606,232 shares and shared dispositive power over 2,737,752 shares, with no sole voting or dispositive power. The position is held through investment management affiliates, including SSGA Funds Management and various State Street Global Advisors entities, and is certified as being held in the ordinary course of business without the purpose of influencing control.
CareDx Chief Operating Officer Kennedy Keith reported equity compensation and related tax withholding transactions in company common stock. On February 2, 2026, Keith received 60,000 shares represented by restricted stock units at $0 per share, which will vest over three years starting April 6, 2027. Keith also acquired 14,474 shares from performance-based restricted stock units that were earned after performance goals were certified on February 2, 2026. To cover tax obligations from the PRSU vesting, 4,644 shares were withheld at a price of $20.42 per share. After these transactions, Keith directly owns 209,139 CareDx common shares.
CareDx, Inc. Chief Commercial Officer Jessica Meng reported equity awards and a related tax withholding transaction. On February 2, 2026, she was granted 60,000 restricted stock units (RSUs), which vest one-third on April 6, 2027 and the remaining two-thirds in eight equal quarterly installments so that all RSUs vest by the third anniversary of April 6, 2027, subject to continuous employment. She also earned 11,579 shares from a performance restricted stock unit (PRSU) award initially granted on February 1, 2025, after performance criteria were certified on February 2, 2026. In connection with the PRSU vesting, 4,430 shares of common stock were withheld at $20.42 per share to satisfy tax withholding obligations, leaving her with 176,778 directly held common shares.
CareDx, Inc. Chief Financial Officer Nathan Smith reported equity compensation and related tax withholding transactions. On February 2, 2026 he was granted 33,000 restricted stock units, which will vest in stages beginning April 6, 2027 and fully vest three years after that date, subject to continued employment.
He also acquired 7,875 common shares at no cost from a performance RSU award that was originally granted on February 1, 2025 and earned after performance goals were certified on February 2, 2026. To cover tax withholding on the PRSU vesting, 3,859 shares were withheld at a price of $20.42 per share, leaving him with 79,016 directly owned shares.